Drug updated on 10/18/2024
| Dosage Form | Injection (intramuscular; 50 Units or 100 Units) |
| Drug Class | Acetylcholine release inhibitors and neuromuscular blocking agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
Latest News
Summary
- This summary is based on the review of one randomized controlled trial(s). [1]
- Psychological Impact and Quality of Life Improvement: LetibotulinumtoxinA significantly reduced the psychological impact of glabellar lines, with a mean improvement of -33.84 on the Modified Skindex-16 GL-QoL Scale compared to -1.37 in the placebo group (p < .001). It also led to notable improvements in quality of life and satisfaction with treatment outcomes.
- Perceived Age and Glabellar Line Severity: Subjects treated with letibotulinumtoxinA reported a younger perceived age on the FACE-Q Age Appraisal Visual Analog Scale. The reduction in psychological burden was highly correlated with improvements in glabellar line severity (p < .0001).
- Lack of Subgroup or Population Differences: The study does not provide specific effectiveness data for different population types or subgroups.
- There is no safety information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Letybo (letibotulinumtoxinA-wlbg) Prescribing Information. | 2024 | Hugel, Inc., 61-20 Sinbuk-ro, Sinbuk-eup_Chuncheon, 24206 Korea |
Randomized Controlled Trials
| Document Title | Sex Distribution | Year | Source |
|---|---|---|---|
| LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is Associated With High Subject Satisfaction in Phase 3 Clinical Trials | Data not availableSubjects F: null% M: null% | 2024 | Dermatologic surgery |
Sex Distribution:
Year:
2024
Source:Dermatologic surgery